Photo by thinkmagically from unsplash
Administration of the non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist phencyclidine (PCP) to rodents has been used as the gold standard preclinical model for schizophrenia. PCP treatment induces hyperlocomotion and stereotypic behaviour,… Click to show full abstract
Administration of the non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist phencyclidine (PCP) to rodents has been used as the gold standard preclinical model for schizophrenia. PCP treatment induces hyperlocomotion and stereotypic behaviour, which resemble the positive symptoms of schizophrenia. In addition, proteomic studies have identified changes in proteins associated with energy metabolism and neurotransmission which are typical hallmarks of the disease. This chapter presents a protocol for the generation of this model, behavioural assessment and preparation of key bio-samples to provide the raw materials for proteomic analyses.
Journal Title: Advances in experimental medicine and biology
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!